KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Common Equity (2017 - 2025)

Twist Bioscience (TWST) has disclosed Common Equity for 9 consecutive years, with $456.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity changed 0.03% to $456.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $456.1 million through Dec 2025, changed 0.03% year-over-year, with the annual reading at $473.0 million for FY2025, 0.06% changed from the prior year.
  • Common Equity for Q4 2025 was $456.1 million at Twist Bioscience, down from $473.0 million in the prior quarter.
  • The five-year high for Common Equity was $863.4 million in Q1 2022, with the low at $440.1 million in Q1 2025.
  • Average Common Equity over 5 years is $602.7 million, with a median of $600.2 million recorded in 2021.
  • The sharpest move saw Common Equity soared 132.47% in 2021, then dropped 25.31% in 2024.
  • Over 5 years, Common Equity stood at $626.2 million in 2021, then increased by 19.19% to $746.3 million in 2022, then decreased by 20.94% to $590.0 million in 2023, then dropped by 22.73% to $455.9 million in 2024, then grew by 0.03% to $456.1 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $456.1 million, $473.0 million, and $478.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.